speb/financial-data huggingface dataset:
DMX.V balance_sheet (quarterly, 2025-09-30) — Invested Capital: 19616491.00
DMX.V cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -755097.00
DMX.V income_statement (quarterly, 2025-09-30) — Net Income: -362990.00
DMX.V income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -362990.00
DMX.V income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -362990.00
DMX.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -362990.00
DMX.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -362990.00
DMX.V cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -362990.00
DMX.V income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -362990.00
DMX.V income_statement (quarterly, 2025-09-30) — Net Interest Income: 65349.00
DMX.V income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 65349.00
DMX.V cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -2055.00
DMX.V cash_flow (quarterly, 2025-09-30) — Net Other Investing Changes: -755097.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Net PPE: 10032217.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 19616491.00
DMX.V income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -572114.00
DMX.V income_statement (quarterly, 2025-09-30) — Normalized Income: -424844.00
DMX.V cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -627622.00
DMX.V income_statement (quarterly, 2025-09-30) — Operating Income: -510260.00
DMX.V income_statement (quarterly, 2025-09-30) — Operating Revenue: 0.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 166685893.00
DMX.V income_statement (quarterly, 2025-09-30) — Other Gand A: 247332.00
DMX.V income_statement (quarterly, 2025-09-30) — Other Income Expense: 81921.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 24250.00
DMX.V income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 20067.00
DMX.V income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 26224.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Other Receivables: 66581.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 200000.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Payables: 146858.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 273081.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 123404.00
DMX.V income_statement (quarterly, 2025-09-30) — Pretax Income: -362990.00
DMX.V cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 882076.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Receivables: 272244.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Restricted Cash: 221343.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -67446263.00
DMX.V income_statement (quarterly, 2025-09-30) — Salaries And Wages: 170025.00
DMX.V income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 66679.00
DMX.V income_statement (quarterly, 2025-09-30) — Selling General And Administration: 484036.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Share Issued: 166685893.00
DMX.V income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
DMX.V cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 170025.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 19616491.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 19616491.00
DMX.V income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
DMX.V income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Total Assets: 19889572.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 19616491.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 19616491.00
DMX.V income_statement (quarterly, 2025-09-30) — Total Expenses: 510260.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 273081.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 10056467.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 0.00
DMX.V income_statement (quarterly, 2025-09-30) — Total Unusual Items: 61854.00
DMX.V income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 61854.00
DMX.V cash_flow (quarterly, 2025-09-30) — Unrealized Gain Loss On Investment Securities: -50000.00
DMX.V balance_sheet (quarterly, 2025-09-30) — Working Capital: 9560024.00
DMX.V income_statement (quarterly, 2025-12-31) — +Operating Expense: 955263.00
DMX.V income_statement (quarterly, 2025-12-31) — +Total Revenue: 0.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 270650.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 36324.00
DMX.V income_statement (quarterly, 2025-12-31) — Basic Average Shares: 167708490.00
DMX.V income_statement (quarterly, 2025-12-31) — Basic EPS: 0.00
DMX.V cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 9237457.00
DMX.V cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -772112.00
DMX.V cash_flow (quarterly, 2025-12-31) — Capital Expenditure Reported: -772112.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Capital Stock: 84453164.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 8817495.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 9354995.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Cash Equivalents: 7613008.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Cash Financial: 1204487.00
DMX.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 901507.00
DMX.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -788144.00
DMX.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -533325.00
DMX.V cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: 133162.00
DMX.V cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 246126.00
DMX.V cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -199328.00
DMX.V cash_flow (quarterly, 2025-12-31) — Change In Receivables: -10330.00
DMX.V cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 169630.00
DMX.V cash_flow (quarterly, 2025-12-31) — Changes In Cash: -419962.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Common Stock: 84453164.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 20003580.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 222624.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Current Assets: 9753239.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 0.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 493274.00
DMX.V income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 167708490.00
DMX.V income_statement (quarterly, 2025-12-31) — Diluted EPS: 0.00
DMX.V income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -684443.00
DMX.V income_statement (quarterly, 2025-12-31) — EBIT: -955263.00
DMX.V income_statement (quarterly, 2025-12-31) — EBITDA: -955263.00
DMX.V cash_flow (quarterly, 2025-12-31) — End Cash Position: 8817495.00
DMX.V cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 901507.00
DMX.V cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -533325.00
DMX.V income_statement (quarterly, 2025-12-31) — Gain On Sale Of Ppe: 106037.00
DMX.V income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: 82625.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 3681122.00
DMX.V income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 770650.00
DMX.V income_statement (quarterly, 2025-12-31) — Impairment Of Capital Assets: 0.00
DMX.V cash_flow (quarterly, 2025-12-31) — Income Tax Paid Supplemental Data: 0.00
DMX.V income_statement (quarterly, 2025-12-31) — Interest Income: 68201.00
DMX.V income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 68201.00
DMX.V cash_flow (quarterly, 2025-12-31) — Interest Paid Supplemental Data: 0.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Invested Capital: 20003580.00
DMX.V cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -788144.00
DMX.V income_statement (quarterly, 2025-12-31) — Net Income: -684443.00
DMX.V income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -684443.00
DMX.V income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -684450.00
DMX.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -684443.00
DMX.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -684443.00
DMX.V cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -684443.00
DMX.V income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -684450.00
DMX.V income_statement (quarterly, 2025-12-31) — Net Interest Income: 68201.00
DMX.V income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 68201.00
DMX.V cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -2414.00
DMX.V cash_flow (quarterly, 2025-12-31) — Net Other Investing Changes: -788144.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Net PPE: 10718988.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 20003580.00
DMX.V income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -1143925.00
DMX.V income_statement (quarterly, 2025-12-31) — Normalized Income: -873105.00
DMX.V cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -533325.00
DMX.V income_statement (quarterly, 2025-12-31) — Operating Income: -955263.00
DMX.V income_statement (quarterly, 2025-12-31) — Operating Revenue: 0.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 169121413.00
DMX.V income_statement (quarterly, 2025-12-31) — Other Gand A: 600625.00
DMX.V income_statement (quarterly, 2025-12-31) — Other Income Expense: 202612.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 24627.00
DMX.V income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 13950.00
DMX.V income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 58260.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Other Receivables: 39188.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 537500.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Payables: 270650.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 493274.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 322732.00
DMX.V income_statement (quarterly, 2025-12-31) — Pretax Income: -684450.00
DMX.V cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 903921.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Receivables: 75512.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -68130706.00
DMX.V income_statement (quarterly, 2025-12-31) — Salaries And Wages: 170025.00
DMX.V income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 126353.00
DMX.V income_statement (quarterly, 2025-12-31) — Selling General And Administration: 897003.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Share Issued: 169121413.00
DMX.V income_statement (quarterly, 2025-12-31) — Special Income Charges: 106037.00
DMX.V cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 170025.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 20003580.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 20003580.00
DMX.V income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
DMX.V income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Total Assets: 20496854.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 20003580.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 20003580.00
DMX.V income_statement (quarterly, 2025-12-31) — Total Expenses: 955263.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 493274.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 10743615.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
DMX.V income_statement (quarterly, 2025-12-31) — Total Unusual Items: 188662.00
DMX.V income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 188662.00
DMX.V cash_flow (quarterly, 2025-12-31) — Unrealized Gain Loss On Investment Securities: -82500.00
DMX.V balance_sheet (quarterly, 2025-12-31) — Working Capital: 9259965.00
DMX.V income_statement (quarterly, 2026-03-31) — +Operating Expense: 784880.00
DMX.V income_statement (quarterly, 2026-03-31) — +Total Revenue: 0.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 168091.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 53807.00
DMX.V income_statement (quarterly, 2026-03-31) — Basic Average Shares: 174151767.00
DMX.V income_statement (quarterly, 2026-03-31) — Basic EPS: 0.00
DMX.V cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 8817495.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Capital Stock: 89497471.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 8141850.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 8641850.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 6449327.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Cash Financial: 1692523.00
DMX.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 823471.00
DMX.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -661435.00
DMX.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -837681.00
DMX.V cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: 0.00
DMX.V cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -252608.00
DMX.V cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -33458.00
DMX.V cash_flow (quarterly, 2026-03-31) — Change In Receivables: 4088.00
DMX.V cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -281978.00
DMX.V cash_flow (quarterly, 2026-03-31) — Changes In Cash: -675645.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Common Stock: 89497471.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 24398848.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 136650.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Current Assets: 9069464.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 0.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 304741.00
DMX.V income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 174151767.00
DMX.V income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.00
DMX.V income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -796590.00
DMX.V income_statement (quarterly, 2026-03-31) — EBIT: -784880.00
DMX.V income_statement (quarterly, 2026-03-31) — EBITDA: -784880.00
DMX.V cash_flow (quarterly, 2026-03-31) — End Cash Position: 8141850.00
DMX.V cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 823471.00
DMX.V cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -837681.00
DMX.V cash_flow (quarterly, 2026-03-31) — Gain Loss On Sale Of PPE: 0.00
DMX.V income_statement (quarterly, 2026-03-31) — Gain On Sale Of Ppe: 0.00
DMX.V income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -63616.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: 3828087.00
DMX.V income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 658059.00
DMX.V income_statement (quarterly, 2026-03-31) — Impairment Of Capital Assets: 0.00
DMX.V cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 0.00
DMX.V income_statement (quarterly, 2026-03-31) — Interest Income: 57814.00
DMX.V income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 57814.00
DMX.V cash_flow (quarterly, 2026-03-31) — Interest Paid Supplemental Data: 0.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Invested Capital: 24398848.00
DMX.V cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -661435.00
DMX.V income_statement (quarterly, 2026-03-31) — Net Income: -796590.00
DMX.V income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -796590.00
DMX.V income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -796590.00
DMX.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -796590.00
DMX.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -796590.00
DMX.V cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -796590.00
DMX.V income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -796590.00
DMX.V income_statement (quarterly, 2026-03-31) — Net Interest Income: 57814.00
DMX.V income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 57814.00
DMX.V cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -5423.00
DMX.V cash_flow (quarterly, 2026-03-31) — Net Other Investing Changes: -661435.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Net PPE: 15149394.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 24398848.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 484731.00
DMX.V income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -721264.00
DMX.V income_statement (quarterly, 2026-03-31) — Normalized Income: -732974.00
DMX.V cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -837681.00
DMX.V cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 0.00
DMX.V income_statement (quarterly, 2026-03-31) — Operating Income: -784880.00
DMX.V income_statement (quarterly, 2026-03-31) — Operating Revenue: 0.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 176031539.00
DMX.V income_statement (quarterly, 2026-03-31) — Other Gand A: 454672.00
DMX.V income_statement (quarterly, 2026-03-31) — Other Income Expense: -69524.00
DMX.V income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -5908.00
DMX.V income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 41861.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Other Receivables: 17617.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 500000.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Payables: 168091.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 304741.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 356190.00
DMX.V income_statement (quarterly, 2026-03-31) — Pretax Income: -796590.00
DMX.V cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 828894.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Receivables: 71424.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -68926710.00
DMX.V income_statement (quarterly, 2026-03-31) — Salaries And Wages: 203387.00
DMX.V income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 84960.00
DMX.V income_statement (quarterly, 2026-03-31) — Selling General And Administration: 743019.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Share Issued: 176031539.00
DMX.V income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
DMX.V cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 203387.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 24398848.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 24398848.00
DMX.V income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
DMX.V income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Total Assets: 24703589.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 24398848.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 24398848.00
DMX.V income_statement (quarterly, 2026-03-31) — Total Expenses: 784880.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 304741.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 15634125.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 0.00
DMX.V income_statement (quarterly, 2026-03-31) — Total Unusual Items: -63616.00
DMX.V income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -63616.00
DMX.V cash_flow (quarterly, 2026-03-31) — Unrealized Gain Loss On Investment Securities: 37500.00
DMX.V balance_sheet (quarterly, 2026-03-31) — Working Capital: 8764723.00
DNA cash_flow (annual, 2021-12-31) — Change In Inventory: -626000.00
DNA cash_flow (annual, 2021-12-31) — Common Stock Payments: -24998000.00
DNA cash_flow (annual, 2021-12-31) — Depreciation: 29076000.00
DNA balance_sheet (annual, 2021-12-31) — Derivative Product Liabilities: 135838000.00
DNA balance_sheet (annual, 2021-12-31) — Finished Goods: 3264000.00
DNA balance_sheet (annual, 2021-12-31) — Goodwill: 21312000.00
DNA balance_sheet (annual, 2021-12-31) — Inventories Adjustments Allowances: -16000.00
DNA balance_sheet (annual, 2021-12-31) — Inventory: 3362000.00
DNA balance_sheet (annual, 2021-12-31) — Loans Receivable: 11559000.00
DNA balance_sheet (annual, 2021-12-31) — Long Term Equity Investment: 13194000.00
DNA balance_sheet (annual, 2021-12-31) — Minority Interest: 62014000.00
DNA income_statement (annual, 2021-12-31) — Minority Interests: 6595000.00
DNA cash_flow (annual, 2021-12-31) — Net Preferred Stock Issuance: 0.00
DNA balance_sheet (annual, 2021-12-31) — Non Current Note Receivables: 0.00
DNA balance_sheet (annual, 2021-12-31) — Notes Receivable: 11559000.00
DNA balance_sheet (annual, 2021-12-31) — Other Receivables: 2198000.00
DNA income_statement (annual, 2021-12-31) — Other Special Charges: -23826000.00
DNA income_statement (annual, 2021-12-31) — Otherunder Preferred Stock Dividend: 58615000.00
DNA cash_flow (annual, 2021-12-31) — Preferred Stock Issuance: 0.00
DNA balance_sheet (annual, 2021-12-31) — Prepaid Assets: 19082000.00
DNA balance_sheet (annual, 2021-12-31) — Raw Materials: 64000.00
DNA cash_flow (annual, 2021-12-31) — Repurchase Of Capital Stock: -24998000.00
DNA balance_sheet (annual, 2021-12-31) — Restricted Cash: 0.00
DNA balance_sheet (annual, 2021-12-31) — Treasury Shares Number: 79598663.00
DNA balance_sheet (annual, 2021-12-31) — Work In Process: 50000.00
DNA income_statement (annual, 2022-12-31) — +Operating Expense: 2482442000.00
DNA income_statement (annual, 2022-12-31) — +Total Revenue: 477706000.00
DNA balance_sheet (annual, 2022-12-31) — Accounts Payable: 10451000.00
DNA balance_sheet (annual, 2022-12-31) — Accounts Receivable: 82465000.00
DNA balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -92756000.00
DNA balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 6136378000.00
DNA balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: -1100000.00
DNA cash_flow (annual, 2022-12-31) — Asset Impairment Charge: 0.00
DNA balance_sheet (annual, 2022-12-31) — Available For Sale Securities: 88143000.00
DNA income_statement (annual, 2022-12-31) — Basic Average Shares: 41976536.00
DNA income_statement (annual, 2022-12-31) — Basic EPS: -50.00
DNA cash_flow (annual, 2022-12-31) — Beginning Cash Position: 1592928000.00
DNA balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 46019000.00
DNA cash_flow (annual, 2022-12-31) — Capital Expenditure: -52271000.00
DNA balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 442588000.00
DNA balance_sheet (annual, 2022-12-31) — Capital Stock: 190000.00
DNA balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 1315792000.00
DNA balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 1315792000.00
DNA cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 95337000.00
DNA cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -67394000.00
DNA cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -252198000.00
DNA cash_flow (annual, 2022-12-31) — Change In Account Payable: -10844000.00
DNA cash_flow (annual, 2022-12-31) — Change In Accrued Expense: -39639000.00
DNA cash_flow (annual, 2022-12-31) — Change In Inventory: 164000.00
DNA cash_flow (annual, 2022-12-31) — Change In Other Current Assets: 14154000.00
DNA cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: -10761000.00
DNA cash_flow (annual, 2022-12-31) — Change In Other Working Capital: -36417000.00
DNA cash_flow (annual, 2022-12-31) — Change In Payable: -10844000.00
DNA cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -50483000.00
DNA cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -8523000.00
DNA cash_flow (annual, 2022-12-31) — Change In Receivables: 55024000.00
DNA cash_flow (annual, 2022-12-31) — Change In Working Capital: -37006000.00
DNA cash_flow (annual, 2022-12-31) — Changes In Account Receivables: 55024000.00
DNA cash_flow (annual, 2022-12-31) — Changes In Cash: -224255000.00
DNA balance_sheet (annual, 2022-12-31) — Common Stock: 190000.00
DNA balance_sheet (annual, 2022-12-31) — Common Stock Equity: 1736277000.00
DNA cash_flow (annual, 2022-12-31) — Common Stock Issuance: 99303000.00
DNA cash_flow (annual, 2022-12-31) — Common Stock Payments: 0.00
DNA balance_sheet (annual, 2022-12-31) — Construction In Progress: 23426000.00
DNA income_statement (annual, 2022-12-31) — Cost Of Revenue: 204216000.00
DNA balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 32857000.00
DNA balance_sheet (annual, 2022-12-31) — Current Assets: 1450079000.00
DNA balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 29332000.00
DNA balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 29332000.00
DNA balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 47817000.00
DNA balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 47817000.00
DNA balance_sheet (annual, 2022-12-31) — Current Liabilities: 172962000.00
DNA cash_flow (annual, 2022-12-31) — Deferred Income Tax: -14609000.00
DNA cash_flow (annual, 2022-12-31) — Deferred Tax: -14609000.00
DNA cash_flow (annual, 2022-12-31) — Depreciation: 44423000.00
DNA cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 42552000.00
DNA cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 42552000.00
DNA balance_sheet (annual, 2022-12-31) — Derivative Product Liabilities: 10868000.00
DNA income_statement (annual, 2022-12-31) — Diluted Average Shares: 41995971.00
DNA income_statement (annual, 2022-12-31) — Diluted EPS: -50.00
DNA income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -2104929000.00
DNA balance_sheet (annual, 2022-12-31) — Duefrom Related Parties Current: 1558000.00
DNA income_statement (annual, 2022-12-31) — EBIT: -2121293000.00
DNA income_statement (annual, 2022-12-31) — EBITDA: -2078741000.00
DNA income_statement (annual, 2022-12-31) — Earnings From Equity Interest: -43761000.00
DNA cash_flow (annual, 2022-12-31) — Earnings Losses From Equity Investments: 43761000.00
DNA cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: 908000.00
DNA cash_flow (annual, 2022-12-31) — End Cash Position: 1369581000.00
DNA balance_sheet (annual, 2022-12-31) — Financial Assets: 1937000.00
DNA cash_flow (annual, 2022-12-31) — Financing Cash Flow: 95337000.00
DNA balance_sheet (annual, 2022-12-31) — Finished Goods: 6556000.00
DNA cash_flow (annual, 2022-12-31) — Free Cash Flow: -304469000.00
DNA cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: -71635000.00
DNA cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of Business: -31889000.00
DNA cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: 3091000.00
DNA income_statement (annual, 2022-12-31) — Gain On Sale Of Business: 31889000.00
DNA income_statement (annual, 2022-12-31) — Gain On Sale Of Security: 71635000.00
DNA balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -2632000.00
DNA income_statement (annual, 2022-12-31) — General And Administrative Expense: 1429799000.00
DNA balance_sheet (annual, 2022-12-31) — Goodwill: 60210000.00
DNA balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 171251000.00
DNA balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 83565000.00
DNA balance_sheet (annual, 2022-12-31) — Gross PPE: 811547000.00
DNA income_statement (annual, 2022-12-31) — Gross Profit: 273490000.00
DNA income_statement (annual, 2022-12-31) — Impairment Of Capital Assets: 0.00
DNA cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 0.00
DNA income_statement (annual, 2022-12-31) — Interest Expense: 106000.00
DNA income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 106000.00
DNA income_statement (annual, 2022-12-31) — Interest Income: 20262000.00
DNA income_statement (annual, 2022-12-31) — Interest Income Non Operating: 20262000.00
DNA cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 92000.00
DNA balance_sheet (annual, 2022-12-31) — Inventories Adjustments Allowances: -3782000.00
DNA balance_sheet (annual, 2022-12-31) — Inventory: 4364000.00
DNA balance_sheet (annual, 2022-12-31) — Invested Capital: 1736277000.00
DNA cash_flow (annual, 2022-12-31) — Investing Cash Flow: -67394000.00
DNA balance_sheet (annual, 2022-12-31) — Investmentin Financial Assets: 88143000.00
DNA balance_sheet (annual, 2022-12-31) — Investments And Advances: 111794000.00
DNA cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 99303000.00
DNA balance_sheet (annual, 2022-12-31) — Land And Improvements: 6060000.00
DNA balance_sheet (annual, 2022-12-31) — Leases: 125307000.00
DNA balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 413256000.00
DNA balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 413256000.00
DNA cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -1237000.00
DNA balance_sheet (annual, 2022-12-31) — Long Term Equity Investment: 1543000.00
DNA balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 23425000.00
DNA balance_sheet (annual, 2022-12-31) — Minority Interest: 0.00
DNA income_statement (annual, 2022-12-31) — Minority Interests: 1443000.00
DNA cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: 26646000.00
DNA cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 99303000.00
DNA income_statement (annual, 2022-12-31) — Net Income: -2104929000.00
DNA income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -2104929000.00
DNA income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -2106372000.00
DNA income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -2104929000.00
DNA income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -2104929000.00
DNA cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -2106372000.00
DNA income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -2106372000.00
DNA income_statement (annual, 2022-12-31) — Net Interest Income: 20156000.00
DNA cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -3691000.00
DNA cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -1237000.00
DNA cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -1237000.00
DNA income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 20156000.00
DNA cash_flow (annual, 2022-12-31) — Net Other Financing Charges: -2969000.00
DNA cash_flow (annual, 2022-12-31) — Net Other Investing Changes: -38078000.00
DNA balance_sheet (annual, 2022-12-31) — Net PPE: 718791000.00
DNA cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -52271000.00
DNA cash_flow (annual, 2022-12-31) — Net Preferred Stock Issuance: 0.00
DNA balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 1565026000.00
DNA balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 174767000.00
DNA balance_sheet (annual, 2022-12-31) — Non Current Deferred Revenue: 174767000.00
DNA balance_sheet (annual, 2022-12-31) — Non Current Note Receivables: 37660000.00
DNA income_statement (annual, 2022-12-31) — Normalized EBITDA: -2182265000.00
DNA income_statement (annual, 2022-12-31) — Normalized Income: -2207719684.32
DNA balance_sheet (annual, 2022-12-31) — Notes Receivable: 0.00
DNA cash_flow (annual, 2022-12-31) — Operating Cash Flow: -252198000.00
DNA cash_flow (annual, 2022-12-31) — Operating Gains Losses: -56672000.00
DNA income_statement (annual, 2022-12-31) — Operating Income: -2208952000.00
DNA income_statement (annual, 2022-12-31) — Operating Revenue: 477706000.00
DNA balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 47299399.00
DNA balance_sheet (annual, 2022-12-31) — Other Current Assets: 487000.00
DNA balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 33064000.00
DNA balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -2632000.00
DNA income_statement (annual, 2022-12-31) — Other Gand A: 1429799000.00
DNA income_statement (annual, 2022-12-31) — Other Income Expense: 67397000.00
DNA balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 111041000.00
DNA balance_sheet (annual, 2022-12-31) — Other Investments: 22108000.00
DNA cash_flow (annual, 2022-12-31) — Other Non Cash Items: -10732000.00
DNA balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 47809000.00
DNA balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: 31191000.00
DNA income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: 7634000.00
DNA balance_sheet (annual, 2022-12-31) — Other Properties: 587310000.00
DNA balance_sheet (annual, 2022-12-31) — Other Receivables: 1561000.00
DNA income_statement (annual, 2022-12-31) — Otherunder Preferred Stock Dividend: 3143000.00
DNA balance_sheet (annual, 2022-12-31) — Payables: 10451000.00
DNA balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 43308000.00
DNA balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 19441000.00
DNA balance_sheet (annual, 2022-12-31) — Preferred Stock: 0.00
DNA cash_flow (annual, 2022-12-31) — Preferred Stock Issuance: 0.00
DNA balance_sheet (annual, 2022-12-31) — Prepaid Assets: 37189000.00
DNA income_statement (annual, 2022-12-31) — Pretax Income: -2121399000.00
DNA cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 240000.00
DNA balance_sheet (annual, 2022-12-31) — Properties: 0.00
DNA cash_flow (annual, 2022-12-31) — Purchase Of Business: -55721000.00
DNA cash_flow (annual, 2022-12-31) — Purchase Of Investment: -3691000.00
DNA cash_flow (annual, 2022-12-31) — Purchase Of PPE: -52271000.00
DNA balance_sheet (annual, 2022-12-31) — Raw Materials: 1590000.00
DNA balance_sheet (annual, 2022-12-31) — Receivables: 84026000.00
DNA income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 204216000.00
DNA income_statement (annual, 2022-12-31) — Reconciled Depreciation: 42552000.00
DNA cash_flow (annual, 2022-12-31) — Repayment Of Debt: -1237000.00
DNA cash_flow (annual, 2022-12-31) — Repurchase Of Capital Stock: 0.00
DNA income_statement (annual, 2022-12-31) — Research And Development: 1052643000.00
DNA balance_sheet (annual, 2022-12-31) — Restricted Cash: 8221000.00
DNA income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 0.00
DNA balance_sheet (annual, 2022-12-31) — Retained Earnings: -4397659000.00
DNA cash_flow (annual, 2022-12-31) — Sale Of Business: 82367000.00
DNA cash_flow (annual, 2022-12-31) — Sale Of Investment: 0.00
DNA cash_flow (annual, 2022-12-31) — Sale Of PPE: 0.00
DNA income_statement (annual, 2022-12-31) — Selling General And Administration: 1429799000.00
DNA balance_sheet (annual, 2022-12-31) — Share Issued: 47299399.00
DNA income_statement (annual, 2022-12-31) — Special Income Charges: 31889000.00
DNA cash_flow (annual, 2022-12-31) — Stock Based Compensation: 1930641000.00
DNA balance_sheet (annual, 2022-12-31) — Stockholders Equity: 1736277000.00
DNA balance_sheet (annual, 2022-12-31) — Tangible Book Value: 1565026000.00
DNA income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 733315.68
DNA income_statement (annual, 2022-12-31) — Tax Provision: -15027000.00
DNA income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.01
DNA balance_sheet (annual, 2022-12-31) — Total Assets: 2539321000.00
DNA balance_sheet (annual, 2022-12-31) — Total Capitalization: 1736277000.00
DNA balance_sheet (annual, 2022-12-31) — Total Debt: 442588000.00
DNA balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 1736277000.00
DNA income_statement (annual, 2022-12-31) — Total Expenses: 2686658000.00
DNA balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 803044000.00
DNA balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 1089242000.00
DNA balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 630082000.00
DNA income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -2208952000.00
DNA income_statement (annual, 2022-12-31) — Total Unusual Items: 103524000.00
DNA income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 103524000.00
DNA balance_sheet (annual, 2022-12-31) — Work In Process: 0.00
DNA balance_sheet (annual, 2022-12-31) — Working Capital: 1277117000.00
DNA income_statement (annual, 2023-12-31) — +Operating Expense: 965646000.00
DNA income_statement (annual, 2023-12-31) — +Total Revenue: 251455000.00
DNA balance_sheet (annual, 2023-12-31) — Accounts Payable: 9323000.00
DNA balance_sheet (annual, 2023-12-31) — Accounts Receivable: 17157000.00
DNA balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -120718000.00
DNA balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 6386191000.00
DNA balance_sheet (annual, 2023-12-31) — Allowance For Doubtful Accounts Receivable: -1000000.00
DNA cash_flow (annual, 2023-12-31) — Amortization Of Securities: 0.00
DNA cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 121404000.00
DNA balance_sheet (annual, 2023-12-31) — Available For Sale Securities: 54013000.00
DNA income_statement (annual, 2023-12-31) — Basic Average Shares: 48610507.00
DNA income_statement (annual, 2023-12-31) — Basic EPS: -18.37
DNA cash_flow (annual, 2023-12-31) — Beginning Cash Position: 1369581000.00
DNA balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 47034000.00
DNA cash_flow (annual, 2023-12-31) — Capital Expenditure: -40801000.00
DNA balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 239309000.00
DNA balance_sheet (annual, 2023-12-31) — Capital Stock: 5000.00
DNA balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 944073000.00
DNA balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 944073000.00
DNA cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -3216000.00
DNA cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -80693000.00
DNA cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -295500000.00
DNA cash_flow (annual, 2023-12-31) — Change In Account Payable: -1183000.00
DNA cash_flow (annual, 2023-12-31) — Change In Accrued Expense: 16899000.00
DNA cash_flow (annual, 2023-12-31) — Change In Other Current Assets: 11845000.00
DNA cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: -22348000.00
DNA cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -35917000.00
DNA cash_flow (annual, 2023-12-31) — Change In Payable: -1183000.00
DNA cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 15716000.00
DNA cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: 10473000.00
DNA cash_flow (annual, 2023-12-31) — Change In Receivables: 50068000.00
DNA cash_flow (annual, 2023-12-31) — Change In Working Capital: 29837000.00
DNA cash_flow (annual, 2023-12-31) — Changes In Account Receivables: 50068000.00
DNA cash_flow (annual, 2023-12-31) — Changes In Cash: -379409000.00
DNA balance_sheet (annual, 2023-12-31) — Common Stock: 5000.00
DNA balance_sheet (annual, 2023-12-31) — Common Stock Equity: 1097152000.00
DNA cash_flow (annual, 2023-12-31) — Common Stock Issuance: 0.00
DNA cash_flow (annual, 2023-12-31) — Common Stock Payments: 0.00
DNA balance_sheet (annual, 2023-12-31) — Construction In Progress: 15830000.00
DNA income_statement (annual, 2023-12-31) — Cost Of Revenue: 54005000.00
DNA balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 34187000.00
DNA balance_sheet (annual, 2023-12-31) — Current Assets: 1001749000.00
DNA balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 17474000.00
DNA balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 17474000.00
DNA balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 48495000.00
DNA balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 48495000.00
DNA balance_sheet (annual, 2023-12-31) — Current Liabilities: 163860000.00
DNA cash_flow (annual, 2023-12-31) — Deferred Income Tax: -801000.00
DNA cash_flow (annual, 2023-12-31) — Deferred Tax: -801000.00
DNA cash_flow (annual, 2023-12-31) — Depreciation: 71554000.00
DNA cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 70507000.00
DNA cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 70507000.00
DNA balance_sheet (annual, 2023-12-31) — Derivative Product Liabilities: 5700000.00
DNA income_statement (annual, 2023-12-31) — Diluted Average Shares: 48610507.00
DNA income_statement (annual, 2023-12-31) — Diluted EPS: -18.37
DNA income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -892869000.00
DNA balance_sheet (annual, 2023-12-31) — Duefrom Related Parties Current: 742000.00
DNA income_statement (annual, 2023-12-31) — EBIT: -892847000.00
DNA income_statement (annual, 2023-12-31) — EBITDA: -822340000.00
DNA income_statement (annual, 2023-12-31) — Earnings From Equity Interest: -2635000.00
DNA cash_flow (annual, 2023-12-31) — Earnings Losses From Equity Investments: 2635000.00
DNA cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -588000.00
DNA cash_flow (annual, 2023-12-31) — End Cash Position: 989584000.00
DNA balance_sheet (annual, 2023-12-31) — Financial Assets: 654000.00
DNA cash_flow (annual, 2023-12-31) — Financing Cash Flow: -3216000.00
DNA cash_flow (annual, 2023-12-31) — Free Cash Flow: -336301000.00
DNA cash_flow (annual, 2023-12-31) — Gain Loss On Investment Securities: 49659000.00
DNA cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of Business: 42502000.00
DNA cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of PPE: 842000.00
DNA income_statement (annual, 2023-12-31) — Gain On Sale Of Business: -42502000.00
DNA income_statement (annual, 2023-12-31) — Gain On Sale Of Security: -49659000.00
DNA balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: 1484000.00
DNA income_statement (annual, 2023-12-31) — General And Administrative Expense: 385025000.00
DNA balance_sheet (annual, 2023-12-31) — Goodwill: 49238000.00
DNA balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 131979000.00
DNA balance_sheet (annual, 2023-12-31) — Gross Accounts Receivable: 18899000.00
DNA balance_sheet (annual, 2023-12-31) — Gross PPE: 515712000.00
DNA income_statement (annual, 2023-12-31) — Gross Profit: 197450000.00
DNA income_statement (annual, 2023-12-31) — Impairment Of Capital Assets: 96210000.00
DNA cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 670000.00
DNA income_statement (annual, 2023-12-31) — Interest Expense: 93000.00
DNA income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 93000.00
DNA income_statement (annual, 2023-12-31) — Interest Income: 57217000.00
DNA income_statement (annual, 2023-12-31) — Interest Income Non Operating: 57217000.00
DNA cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 83000.00
DNA balance_sheet (annual, 2023-12-31) — Inventory: 46000.00
DNA balance_sheet (annual, 2023-12-31) — Invested Capital: 1097152000.00
DNA cash_flow (annual, 2023-12-31) — Investing Cash Flow: -80693000.00
DNA balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 54013000.00
DNA balance_sheet (annual, 2023-12-31) — Investments And Advances: 77911000.00
DNA cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 0.00
DNA balance_sheet (annual, 2023-12-31) — Land And Improvements: 6060000.00
DNA balance_sheet (annual, 2023-12-31) — Leases: 71564000.00
DNA balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 221835000.00
DNA balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 221835000.00
DNA cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -1295000.00
DNA balance_sheet (annual, 2023-12-31) — Long Term Equity Investment: 0.00
DNA balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 21238000.00
DNA balance_sheet (annual, 2023-12-31) — Minority Interest: 0.00
DNA income_statement (annual, 2023-12-31) — Minority Interests: 0.00
DNA cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: -42980000.00
DNA cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 0.00
DNA income_statement (annual, 2023-12-31) — Net Income: -892869000.00
DNA income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -892869000.00
DNA income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -892869000.00
DNA income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -892869000.00
DNA income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -892869000.00
DNA cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -892869000.00
DNA income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -892869000.00
DNA income_statement (annual, 2023-12-31) — Net Interest Income: 57124000.00
DNA cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 0.00
DNA cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -1295000.00
DNA cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -1295000.00
DNA income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 57124000.00
DNA cash_flow (annual, 2023-12-31) — Net Other Financing Charges: -2014000.00
DNA cash_flow (annual, 2023-12-31) — Net Other Investing Changes: -1340000.00
DNA balance_sheet (annual, 2023-12-31) — Net PPE: 394994000.00
DNA cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -36373000.00
DNA balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 965173000.00
DNA balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 158062000.00
DNA balance_sheet (annual, 2023-12-31) — Non Current Deferred Revenue: 158062000.00
DNA balance_sheet (annual, 2023-12-31) — Non Current Note Receivables: 13601000.00
DNA income_statement (annual, 2023-12-31) — Normalized EBITDA: -633969000.00
DNA income_statement (annual, 2023-12-31) — Normalized Income: -704512977.87
DNA balance_sheet (annual, 2023-12-31) — Notes Receivable: 12293000.00
DNA cash_flow (annual, 2023-12-31) — Operating Cash Flow: -295500000.00
DNA cash_flow (annual, 2023-12-31) — Operating Gains Losses: 95638000.00
DNA income_statement (annual, 2023-12-31) — Operating Income: -768196000.00
DNA income_statement (annual, 2023-12-31) — Operating Revenue: 251455000.00
DNA balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 50032875.00
DNA balance_sheet (annual, 2023-12-31) — Other Current Assets: 39777000.00
DNA balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 38703000.00
DNA balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: 1484000.00